Invesco Pharmaceuticals ETF

PJP · ETF

$125.03−$2.28 (−1.79%)TodayMarket closed ·
Prev close $127.31

About PJP

PJP was created on 2005-06-23 by Invesco. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 550.63m in AUM and 28 holdings. PJP tracks an index of US pharmaceutical companies selected and weighted based on various factors using a quantitative methodology.

Issuer
Invesco
Tracks
Dynamic Pharmaceutical Intellidex Index (AMEX)
Expense ratio
0.58%
Assets under management
$558.37M
Inception
Jun 23, 2005
Asset class
Equity

PJP key statistics

Market cap
0
Price-earnings ratio
0.00
Average volume
37.58K
Volume
6.13K
Open price
$126.66
High today
$126.66
Low today
$124.98
52 Week high
$131.68
52 Week low
$94.69

Invesco Pharmaceuticals ETF (PJP) at a glance

As of Oct 23, 2026, Invesco Pharmaceuticals ETF (PJP) shares are priced at $125.03, giving the company a market cap of 0 and a price-to-earnings ratio of 0.00.

Today the fund has traded between $124.98 and $126.66. The current price is 0.0% above the day's low and 1.3% below its high.

Volume so far is 6.13K shares, below the average of 37.58K shares a day.

Over the past year Invesco Pharmaceuticals ETF has ranged from $94.69 to $131.68, and now sits 82% of the way up that range.

PJP news

  • Vandana Singh

    What's Going On With Amgen Stock Tuesday?

  • Stjepan Kalinic

    Two Years to Build or Pay 200% — Which US Pharma Stocks Win?

  • Vandana Singh

    Amgen Posts 77% Response In Thyroid Eye Disease Study

  • Vandana Singh

    Pfizer's Cancer Drug Combo Shows Strong Results In Key Colorecatal Cancer Trial

  • Rishabh Mishra

    Trump Unveils 'Great Healthcare Plan,' Takes Aim At PBM 'Kickbacks'

  • Rishabh Mishra

    Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily'

  • Rishabh Mishra

    Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms

  • Rishabh Mishra

    Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.